title: Cancer (film)
Skin cancer in horses
Epidemiology of breast cancer
BRCA mutation
Cancer syndrome
Brain metastasis
Tecemotide
Malignant pleural effusion
Uterine cancer
Thin (film)
sentences: Cancer: The Emperor of All Maladies is a 2015 American documentary film directed by Barak Goodman and produced by Ken Burns.
 The film, in three-episodes of two hours each, is based on the Pulitzer Prize winning 2010 book, "", by Siddhartha Mukherjee, and describes the history of cancer, and cancer treatments, particularly in the United States.
Skin cancer, or neoplasia, is the most common type of cancer diagnosed in horses, accounting for 45 to 80% of all cancers diagnosed.
 Sarcoids are the most common type of skin neoplasm and are the most common type of cancer overall in horses.
 Squamous-cell carcinoma is the second-most prevalent skin cancer, followed by melanoma.
 Squamous-cell carcinoma and melanoma usually occur in horses greater than 9-years-old, while sarcoids commonly affect horses 3 to 6 years old.
 Surgical biopsy is the method of choice for diagnosis of most equine skin cancers, but is contraindicated for cases of sarcoids.
 Prognosis and treatment effectiveness varies based on type of cancer, degree of local tissue destruction, evidence of spread to other organs (metastasis) and location of the tumor.
 Not all cancers metastasize and some can be cured or mitigated by surgical removal of the cancerous tissue or through use of chemotherapeutic drugs.
Worldwide, breast cancer is the most common invasive cancer in women.
 (The most common form of cancer is non-invasive non-melanoma skin cancer; non-invasive cancers are generally easily cured, cause very few deaths, and are routinely excluded from cancer statistics.)
 Breast cancer comprises 22.9% of invasive cancers in women and 16% of all female cancers.
A "BRCA" mutation is a mutation in either of the "BRCA1" and "BRCA2" genes, which are tumour suppressor genes.
 Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, while others have no proven impact.
 Harmful mutations in these genes may produce a hereditary breast-ovarian cancer syndrome in affected persons.
 Only 5-10% of breast cancer cases in women are attributed to "BRCA1" and "BRCA2" mutations (with "BRCA1" mutations being slightly more common than "BRCA2" mutations), but the impact on women with the gene mutation is more profound.
 Women with harmful mutations in either "BRCA1" or "BRCA2" have a risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal.
 The risk of breast and ovarian cancer is higher for women with a high-risk "BRCA1" mutation than with a "BRCA2" mutation.
 Having a high-risk mutation does not guarantee that the woman will develop any type of cancer, or imply that any cancer that appears was actually caused by the mutation, rather than some other factor.
A cancer syndrome or family cancer syndrome is a genetic disorder in which inherited genetic mutations in one or more genes predispose the affected individuals to the development of cancers and may also cause the early onset of these cancers.
 Cancer syndromes often show not only a high lifetime risk of developing cancer, but also the development of multiple independent primary tumors.
 Many of these syndromes are caused by mutations in tumor suppressor genes, genes that are involved in protecting the cell from turning cancerous.
 Other genes that may be affected are DNA repair genes, oncogenes and genes involved in the production of blood vessels (angiogenesis).
 Common examples of inherited cancer syndromes are hereditary breast-ovarian cancer syndrome and hereditary non-polyposis colon cancer (Lynch syndrome).
A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor.
 The metastasis typically shares a cancer cell type with the original site of the cancer.
 Metastasis is the most common cause of brain cancer, with tumors originating in the brain being less common.
 The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer.
 Brain metastases can occur in patients months or even years after their original cancer is treated.
 Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years after the diagnosis.
Tecemotide (INN; emepepimut-S (USAN); formerly known as BLP25 or EMD 531444) is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine (formerly known as Stimuvax, L-BLP25, BLP25 liposomal vaccine or BLP25 liposome vaccine).
 The investigational therapeutic cancer vaccine is designed to induce a cellular immune response to cancer cells that express MUC1, a glycoprotein antigen that is widely over-expressed on common cancers such as lung cancer, breast cancer, prostate cancer and colorectal cancer.
 The cellular immune response may lead then to a rejection of tumor tissue expressing the MUC1 antigen.
Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity.
 Lung cancer and breast cancer account for about 50-65% of malignant pleural effusions.
 Other common causes include pleural mesothelioma and lymphoma.
Uterine cancer or womb cancer is any type of cancer that emerges from the tissue of the uterus.
 It can refer to several types of cancer, with cervical cancer (arising from the lower portion of the uterus) being the most common type worldwide and the second most common cancer in women in developing countries.
 Endometrial cancer (or cancer of the inner lining of the uterus) is the second most common type, and fourth most common cancer in women from developed countries.
 Risk factors depend on specific type, but obesity, older age, and human papillomavirus infection add the greatest risk of developing uterine cancer.
 Early on, there may be no symptoms, but irregular vaginal bleeding, pelvic pain or fullness may develop.
 If caught early, most types of uterine cancer can be cured using surgical or medical methods.
 When the cancer has extended beyond the uterine tissue, more advanced treatments including combinations of chemotherapy, radiation therapy, or surgery may be required.
Thin (often styled as THIN) is a 2006 cinéma vérité documentary film directed by Lauren Greenfield and distributed by HBO.
 It was filmed at The Renfrew Center of Florida in Coconut Creek, a 40-bed residential facility for the treatment of women with eating disorders.
 The film follows four women with anorexia nervosa, bulimia nervosa and other eating disorders in their struggle for recovery.
 It premiered to the general public November 14, 2006 on HBO.

Question: Question: Thin and Cancer, have which genre in common? 

 Your answer will be verified with exact match score. To ensure correct verification, only provide the answer within the <answer> </answer> tags. Do not put any sentences or reasoning process within the <answer> </answer> tags. 

Supporting Information: Paragraph 0 

 Cancer: The Emperor of All Maladies is a 2015 American documentary film directed by Barak Goodman and produced by Ken Burns.
 The film, in three-episodes of two hours each, is based on the Pulitzer Prize winning 2010 book, "", by Siddhartha Mukherjee, and describes the history of cancer, and cancer treatments, particularly in the United States. 

--------------------------------

Paragraph 1 

 Worldwide, breast cancer is the most common invasive cancer in women.
 (The most common form of cancer is non-invasive non-melanoma skin cancer; non-invasive cancers are generally easily cured, cause very few deaths, and are routinely excluded from cancer statistics.)
 Breast cancer comprises 22.9% of invasive cancers in women and 16% of all female cancers. 

--------------------------------

Paragraph 2 

 A "BRCA" mutation is a mutation in either of the "BRCA1" and "BRCA2" genes, which are tumour suppressor genes.
 Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, while others have no proven impact.
 Harmful mutations in these genes may produce a hereditary breast-ovarian cancer syndrome in affected persons.
 Only 5-10% of breast cancer cases in women are attributed to "BRCA1" and "BRCA2" mutations (with "BRCA1" mutations being slightly more common than "BRCA2" mutations), but the impact on women with the gene mutation is more profound.
 Women with harmful mutations in either "BRCA1" or "BRCA2" have a risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal.
 The risk of breast and ovarian cancer is higher for women with a high-risk "BRCA1" mutation than with a "BRCA2" mutation.
 Having a high-risk mutation does not guarantee that the woman will develop any type of cancer, or imply that any cancer that appears was actually caused by the mutation, rather than some other factor. 

--------------------------------

Paragraph 3 

 A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor.
 The metastasis typically shares a cancer cell type with the original site of the cancer.
 Metastasis is the most common cause of brain cancer, with tumors originating in the brain being less common.
 The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer.
 Brain metastases can occur in patients months or even years after their original cancer is treated.
 Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years after the diagnosis. 

--------------------------------

Paragraph 4 

 Tecemotide (INN; emepepimut-S (USAN); formerly known as BLP25 or EMD 531444) is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine (formerly known as Stimuvax, L-BLP25, BLP25 liposomal vaccine or BLP25 liposome vaccine).
 The investigational therapeutic cancer vaccine is designed to induce a cellular immune response to cancer cells that express MUC1, a glycoprotein antigen that is widely over-expressed on common cancers such as lung cancer, breast cancer, prostate cancer and colorectal cancer.
 The cellular immune response may lead then to a rejection of tumor tissue expressing the MUC1 antigen. 

--------------------------------

Paragraph 5 

 Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity.
 Lung cancer and breast cancer account for about 50-65% of malignant pleural effusions.
 Other common causes include pleural mesothelioma and lymphoma. 

--------------------------------

Paragraph 6 

 Uterine cancer or womb cancer is any type of cancer that emerges from the tissue of the uterus.
 It can refer to several types of cancer, with cervical cancer (arising from the lower portion of the uterus) being the most common type worldwide and the second most common cancer in women in developing countries.
 Endometrial cancer (or cancer of the inner lining of the uterus) is the second most common type, and fourth most common cancer in women from developed countries.
 Risk factors depend on specific type, but obesity, older age, and human papillomavirus infection add the greatest risk of developing uterine cancer.
 Early on, there may be no symptoms, but irregular vaginal bleeding, pelvic pain or fullness may develop.
 If caught early, most types of uterine cancer can be cured using surgical or medical methods.
 When the cancer has extended beyond the uterine tissue, more advanced treatments including combinations of chemotherapy, radiation therapy, or surgery may be required. 

--------------------------------

Paragraph 7 

 Thin (often styled as THIN) is a 2006 cinéma vérité documentary film directed by Lauren Greenfield and distributed by HBO.
 It was filmed at The Renfrew Center of Florida in Coconut Creek, a 40-bed residential facility for the treatment of women with eating disorders.
 The film follows four women with anorexia nervosa, bulimia nervosa and other eating disorders in their struggle for recovery.
 It premiered to the general public November 14, 2006 on HBO. 

--------------------------------

 


Answer: documentary